Case Report: Recurrent Fungal Keratitis and Blepharitis Caused by *Aspergillus flavus*

Chia-Yi Lee,1,2 Yi-Ju Ho,1 Chi-Chin Sun,3,4 Hsin-Chuang Lin,1,4 Ching-Hsi Hsiao,1,4 David Hui-Kang Ma,1,4,5 Chi-Chun Lai,1,4 and Hung-Chi Chen1,4,5*

1Department of Ophthalmology, Chang Gung Memorial Hospital, Linkou, Taiwan; 2Department of Ophthalmology, Show Chwan Memorial Hospital, Changhua, Taiwan; 3Department of Ophthalmology, Chang Gung Memorial Hospital, Keelung, Taiwan; 4Department of Medicine, Chang Gung University College of Medicine, Taoyuan, Taiwan; 5Center for Tissue Engineering, Chang Gung Memorial Hospital, Linkou, Taiwan

Abstract. *Aspergillus* species produce a wide spectrum of fungal diseases like endophthalmitis and fungal keratitis ophthalmologically, but there has been no report about blepharitis caused by *Aspergillus flavus* to date. Herein, we report a 61-year-old ethnic Han Taiwanese male who had suffered from pain with burning and foreign body sensation after an insect bite on his left eye. Specimens from bilateral eyelids suggested infection of *A. flavus*, whereas corneal scraping showed the presence of Gram-negative bacteria. He was admitted for treatment of infectious keratitis with topical antibiotic and antifungal eye drops. Two weeks after discharge, recurrent blepharitis and keratitis of *A. flavus* was diagnosed microbiologically. Another treatment course of antifungal agent was resumed in the following 6 months, without further significant symptoms in the following 2 years. Collectively, it is possible for *A. flavus* to induce concurrent keratitis and blepharitis, and combined treatment of keratitis as well as blepharitis is advocated for as long as 6 months to ensure no recurrence.

INTRODUCTION

*Aspergillus* species are ubiquitous, and aspergillosis produces a wide spectrum of fungal diseases with variable susceptibility. Although the spores are occasionally inhaled, the fungal species seldom arouse vigorous systemic immune response. Although aspergillosis can be devastating in high-risk individuals, including the immunocompromised, it can still cause asthma, sinusitis, endophthalmitis, and fungal keratitis for those immunocompetent individuals without risk factors.1,2 Among *Aspergillus* species, *Aspergillus flavus* is only less common than *Aspergillus fumigatus* as a cause of invasive aspergillosis in the human body and among the most common *Aspergillus* species causing fungal keratitis.3,4 However, compared with the various pathogens of infectious blepharitis such as bacteria, viruses, and parasites, fungi are rarely encountered.2 To date, there has been no report on blepharitis caused by *A. flavus*. Herein, we report a case of recurrent fungal blepharitis with concurrent keratitis, both of which were salvaged by continuous treatment with topical antifungal agents.

CASE REPORT

A 61-year-old ethnic Han Taiwanese male with previous surgical history of meningioma and cataract had suffered from pain with burning and foreign body sensation after an insect bite on his left eye for 1 week, with associated symptoms of purulent discharge, tearing, hyperemia, and blurred vision. He visited a local clinic where an unknown tiny bug was removed and unknown eye drops were given which were not effective. The patient then visited our clinic of a tertiary hospital, and was admitted due to suspected infectious keratitis. On examination, his best-corrected visual acuity (BCVA) was only counting fingers at the distance of 10 cm for the left eye and was 20/40 for the right eye. Bilateral crusty and thickened eyelid margins, hyperemic at the lash base, and conjunctival injection were noted. Slit-lamp biomicroscopy showed a crescent-shaped, greyish-white corneal stromal infiltration (4.4 × 3.2 mm) with fluffy margins (Figure 1A) located centrally. In addition, partial corneal melting without satellite lesions was also found, whereas the anterior chamber was free of hypopyon. Then, corneal scraping and crust from the eyelid were sent for microbiological investigation.

During admission, the patient was treated with hourly empirical topical fortified antibiotics including cefazolin 25 mg/mL (Union Chemical and Pharmaceutical, Taipei, Taiwan), amikacin 25 mg/mL (Taiwan Biotech, Taoyuan, Taiwan), and antifungal natamycin ophthalmic suspension 5% (Alcon Laboratory, Fort Worth, TX). Specimens from bilateral eyelids showed growth of green-yellow colonies with white edge, suggestive of *A. flavus* (Figure 1B). Light microscopy with methylene blue stain demonstrated conidiophores (Figure 1C) with classical radiate conidia (Figure 1C, inset), whereas corneal scraping from the left eye revealed Gram-negative bacteria only, without evidence of fungal colonization. By the time of discharge, BCVA of left eye improved to 20/200, and slit-lamp revealed significantly decreased corneal opacity and haze with only residual stromal infiltrates (Figure 1D); there was only a central scar with residual punctate epithelial erosions stained with fluorescein (Figure 1D, inset).

However, 14 days after being discharged, the patient returned to our hospital due to progressively blurred vision and lid margin itchiness without ocular pain. On examination, there was greyish-white stromal feathery infiltration extending from the residual central corneal epithelial defect (Figure 2A). Eyelid margin telangiectasia and plugging of meibomian gland orifices indicated flare-up of blepharitis (Figure 2B). For relapsing blepharitis and keratitis without systemic involvement, bilateral eyelid crust and corneal scraping of left eye were sent for microbiological assessments, and the growth from bilateral eyelid specimens turned out as *A. flavus* again. Different to previous management, topical tetracycline ointment 1% (*Synpac-Kindom Pharmaceutical, Taipei, Taiwan) and natamycin ophthalmic suspension 5% (Alcon Laboratory, Fort Worth, TX) were given four times daily and hourly, respectively, for 2 weeks, which were both tapered to twice daily for the succeeding 6 months and the patient had recovered without further symptoms. In the following 2 years, with proper eyelid hygiene, chronic...
blepharitis was much less active without recurrence of keratitis (Figure 2C and D).

**DISCUSSION**

Blepharitis is a chronic eyelid disorder that seldom causes visual impairment, rendering its easily overlooked influence to ocular morbidity. Definite treatment of blepharitis is lacking and recurrence is common. Severe blepharitis usually presents with complications such as conjunctivitis, dry eye syndrome, keratitis, or even corneal ulceration. Although antifungal agent is not recommended as empirical treatment of keratitis, the importance of timely microbiological testing cannot be overemphasized, especially in the case of recurrent keratitis.6
Fungal infection is commonly associated with agriculture or outdoor activities. Our patient, a farmer with a contact history of insects or unknown vegetative matter, was surely a candidate for *Aspergillus*-related infection. Given that fungal infection is usual in immunocompromised individuals, we assumed that there were undetected underlying ocular disorders. The eyelid disorder, such as blepharitis, might have predisposed our patient to keratitis, and prolonged the course of treatment.

The relationship between *A. flavus* infection and blepharitis remains controversial. In a semiquantitative study, colonies of *A. flavus* were isolated from one of 90 eyes with blepharitis, but not from 66 normal eyes. It was indeterminate whether *Aspergillus* spp. would be present because of inflammation on eyelid margins or as being transient flora. In addition, in a case report of vernal keratoconjunctivitis superimposed with *A. flavus* keratitis, it was postulated that transient mold-containing microbiota of external ocular surfaces can really invade and initiate infection in compromised cornea. Accordingly, the preexisting fungal blepharitis in our patient might have caused recurrence of fungal keratitis soon after he was discharged. To prevent recurrence of fungal keratitis, the treatment strategy should include eradication of eyelid mycosis, for which ocular surface protection with tear substitutes as well as extended use of topical antifungal therapy are suggested in chronic blepharitis with suspected fungal keratitis.

To treat *Aspergillus*-related fungal keratitis, there is no gold standard yet. Generally, it is divided into three groups: azoles, polyenes, and allylamines. Topical antifungal agents still remain the major therapeutic choice and first-line treatment, and although there is no single drug or combinations that have proved to be more effective in treating fungal keratitis, amphotericin B, voriconazole, and natamycin are being routinely used to treat fungal keratitis. Natamycin is the only commercially available topical antifungal agent, which is used as the standard regimen in our hospital to treat *Aspergillus*-related fungal keratitis, and the patient’s diseased eye obtained good outcome without recurrence during follow-up after topical natamycin application. We did not consider manufactured amphotericin B eye drops as solitary treatment or double fungal treatments because *Fusarium* infection cannot be excluded initially, on which amphotericin B has minimal effect. Also, the visual acuity of our patient has gradually improved under natamycin administration, so multiple medications or alternation of therapeutic agent seems unnecessary. Given the recurrent tendency of fungal infection, we recommend an extended course of natamycin administration and tapering it according to clinical response. Except for natamycin, use of voriconazole has been described in ophthalmic literatures. As for topical amphotericin B, which is also active against *Aspergillus* spp., it has poorer penetration through cornea with intact epithelium compared with topical natamycin.

In conclusion, it is possible for *A. flavus* to induce concurrent keratitis and blepharitis according to the presentation of our case. The administrations of tetracycline for blepharitis and natamycin for *A. flavus* infection may be considered as an effective treatment, but the therapeutic period should not be shorter than 6 months. Larger case series or clinical trials are merited to recommend more precise dosage and duration of topical antibiotics and to prevent side effects if any.

Received June 7, 2016. Accepted for publication August 7, 2016.

Published online September 12, 2016.

Financial support: This study was supported by the Chang Gung Memorial Hospital (CMRPG3D0901, CMRPG3E0931, and CMRPG3F1471) and the Ministry of Science and Technology (MOST 104-2314-B-182A-007) in Taiwan to Hung-Chi Chen.

Disclaimer: Written informed consent was obtained from the patient for publication of this case report and the accompanying images. A copy of the written consent is available for review by the Editor of this Journal.

Authors’ addresses: Chia-Yi Lee, Department of Ophthalmology, Chang Gung Memorial Hospital, Linkou, Taiwan, and Department of Ophthalmology, Show Chwan Memorial Hospital, Changhua, Taiwan, E-mail: ao6u.3msn@hotmail.com; Yi-Ju Ho, Hsin-Chi Hsiao, Chi-Chun Lai, and Hung-Chi Chen, Department of Ophthalmology, Chang Gung Memorial Hospital, Linkou, Taiwan, E-mails: freedomschild3800@gmail.com, hsinchiuang@gmail.com, hsiaochihi@gmail.com, and mr5750@cgmh.org.tw. Chi-Chin Sun, Department of Ophthalmology, Chang Gung Memorial Hospital, Keelung, Taiwan, E-mail: arvin.sun@msa.hinet.net.

REFERENCES